Тема: Определение соматических мутаций методом фрагментного анализа у пациентов с диагнозом ОМЛ

1 Nakao M. Internal tandem duplication of the FLT3 gene found in acute myeloid leukemia / M. Nakao, S. Yokota, T. Iwai, [et al]. // Leukemia. - 1996. - V.10. -I.12. - P.1911-1918.
2 Meshinchi S. Clinical implications of FLT3 mutations in pediatric AML / S. Meshinchi, T.A. Alonzo, D.L. Stirewalt, [et al]. // Blood. - 2006. -V.108. - I.12. - P.3654-3661.
3 Arber D.A. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia / D.A. Arber, A. Orazi, R. Hasserjian, [et al] // Blood. - 2016. - V.127. - I.20. - P.2391-2405.
4 Dohner H. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel / H. Dohner, E. Estey, D. Grimwade, [et al] // Blood. - 2017. - V.129. - I.4. - P.424-447.
5 Паровичникова Е.Н.. Итоги многоцентрового исследования по лечению острых миелоидных лейкозов взрослых / Е.Н. Паровичникова, В.Г. Савченко,
В.Г Исаев, [и др.] // Терапевтический архив. - 2007. - Т.79. - №7. - С. 14-9.
6 Vardiman J.W. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes / J.W. Vardiman, J. Thiele, D.A. Arber, [et al] // Blood. - 2009. - V.114. - I.5. - P. 937-951.
7 Домнинский Д.А. Гемобластозы миелоидного происхождения / Д.А. Домнинский // Онкогематология. - 2011. - Т.6. - №3. - С.82-93.
8 Савченко В.Г. Острые лейкозы / В.Г.Савченко, Е.Н.Паровичникова // Клиническая онкогематология: руководство для врачей. Под ред. Волковой М.А.. 2-е изд., перераб. и доп. - 2007. - P. 409-502.
9 Kulsoom B. Clinical presentation of acute myeloid leukaemia - A decade¬long institutional follow-up/ B. Kulsoom // J. Pak. Med. Assoc. - 2017. - V. 67. - I.12. - P. 1837-1842.
10 Клинические рекомендации 2020 г. «Острые миелоидные лейкозы» /
Общероссийский национальный союз «Ассоциация онкологов России» [Электронный ресурс] - Режим доступа: https://oncology-
association.ru/files/clinical-guidelines-2020/ostrye_mieloidnye_lejkozy.pdf
11 Juliusson G. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry / G. Juliusson, P. Antunovic, A. Derolf, [et al] // Blood. - 2009. - V.113. - I.18. - P. 4179-87
12 Kantarjian H. Questions regarding frontline therapy of acute myeloid leukemia / H. Kantarjian, S. O'Brien // Cancer. - 2010. - V.116. - I.21. - P.4896-901.
13 Estey E.H. How I treat older patients with AML / E.H. Estey // Blood. - 2000. - V.96. - P.1670-1673.
14 Ok, C. Y. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases / C. Y. Ok, K. P. Patel, G. Garcia-Manero // Leukemia research. - 2015. - V.39. - I.3. - P.348-354.
15 Burnett A.K. Therapeutic advances in acute myeloid leukemia / A.K. Burnett, M. Wetzler, B. Lowenberg // J Clin Oncol. - 2011. - V.29. - I.5. - P.487¬494.
16 Breems D.A. Acute myeloid leukemia and the position of autologous stem cell transplantation / D.A. Breems, B. Lowenberg // Semin Hematol. - 2007. - V.44.
- I.4. - P.259-266.
17 Schlenk R.F. Risk adapted post-remission therapy in acute myeloid leukemia: results of the German Multicenter AML HD93 treatment trial /
R.F.Schlenk, A. Benner, F. Hartmann, [et al]. // Leukemia. - 2003. - V.17. - I.8. - P.1521-1528.
18 Грицаев С.В. Возраст и кариотип - факторы риска у больных первичным острым миелоидным лейкозом / С.В. Грицаев, И.С. Мартынкевич, Л.С. Мартыненко, [и др] // Клиническая онкогематология/ Фундаментальные исследования и клиническая практика. - 2010. - Т.3. - №4. - С.359-364.
19 Флейшман Е.В. Возрастные особенности цитогенетических изменений при острых миелоидных лейкозах / Е.В. Флейшман, О.И. Сокова, А.В. Попа // Онкогематология. - 2007. - Т.4. - С. 12-6.
20 Lowenberg B. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group / B. Lowenberg, R. Zittoun, H. Kerkhofs, [et al] // J Clin Oncol. - 1989. - V.7.
- P.1268-1274.
21 Pulsoni A. Survival of elderly patients with acute myeloid leukemia / A. Pulsoni, L. Pagano, R. Latagliata, [et al] // Haematologica. - 2004. - V.89. - P.296¬302.
22 Ковалева Л.Г. Острые лейкозы. - 2-е изд., перераб. и доп. / Ковалева Л.Г. - М.: Медицина, 1990. - 272 с.
23 Appelbaum F.R. Age and acute myeloid leukemia / F.R. Appelbaum, H. Gundacker, D.R. Head, [et al] // Blood. - 2006. - V.107. - I.9. - P.3481-5.
24 Sekeres M.A. The epidemiology of myelodysplastic syndromes / M.A. Sekeres // Hematol Oncol Clin North Am. - 2010. - V.24. - I.2. - P.287-94.
25 Shallis R.M. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges / R.M. Shallis, [et al]. // Blood. - Rev. 2019. - V. 36. - P. 70-87.
26 Parkin D.M . Cancer Incidence in Five Continents / D.M. Parkin, J. Ferlay, L. Raymond, J. Young // IARC Scientific Pub. - 1997. - V.7. - I.143.
27 Lemmon M. Cell signaling by receptor tyrosine kinases / M. Lemmon, J. Schlessinger // Cell. - 2010. - V.141. - P.1117-34.
28 Toffalini F. New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases / F. Toffalini, J.B. Demoulin // Blood. - 2010. - V. 116. - P.2429-37.
29 Krivtsov A. MLL translocations, histone modifications and leukaemia stem-cell development / A. Krivtsov, S. Armstrong // Nat Rev Cancer. - 2007. - V.7. - P.823-33.
30 Bullinger L. Genomics of Acute Myeloid Leukemia Diagnosis and Pathways / L. Bullinger, K. Dohner, H.Dohner // J Clin Oncol. - 2017. - V.35. - I.9.
- P.934-46.
31 Szankasi P. A new DNA-based test for detection of nucleophosmin exon 12 mutations by capillary electrophoresis / P. Szankasi, M. Jama, D.W. Bahler // J Mol Diagn - 2008. - V. 10. - I.3. - P.236-241.
32 Виноградов А.В. Применение технологии прямого авто- магического секвенирования для детекции мутаций генов ASXL1, DNMT3A, FLT3, KIT, NRAS, TP53 и WT1 при острых миелоидных лейкозах c неуточненным кариотипом / А.В. Виноградов, А.В. Резайкин, Д.В. Изотов, А.Г. Сергеев // Вестник уральской медицинской академической науки. - 2016. - №4. - С. 38¬
51.
33 Metzeler K.H. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia / K.H. Metzeler, T. Herold, M. Rothenberg-Thurle, [et al] // Blood. - 2016. - V. 128. - №5. - P.686-698.
34 Radtke I. Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia / I. Radtke, C. Mullighan, M. Ishii, [et al] // PNAS. - 2009. - V.106. - P.12944-9.
35 Tripon, F. Simultaneous FLT3, NPM1 and DNMT3A mutations in adult patients with acute myeloid leukemia - case study / F. Tripon, G. Crauciuc, V. Moldovan, [et al] // Revista Romana de Medicina de Laborator. - 2019. - V.27. - I.3.
- P. 245-254.
36 Mevatee P. FLT3-ITD, NPM1, and DNMT3A Gene Mutations and Risk Factors in Normal Karyotype Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients in Upper Northern Thailand / P. Mevatee, A. Tantiworawit, P. Traisathit, [et al] // Asian Pac J Cancer Prev. - 2017. - V.18. - I.11. - P.3031-9.
37 Loghavi S. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations / S. Loghavi, Z. Zuo, F. Ravandi, [et al] // J Hematol Oncol. - 2014. - V.7. - P.74.
38 Chou W.C. Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution / W.C. Chou, J.L. Tang, [et al] // Cancer Res. - 2006. - V.66. - P. 3310-3316.
39 Matthews, W. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations / W. Matthews, C. T Jordan, G. W. Wiegand, [et al] // Cell. - 1991. - V.65. - I.7. - P.1143-1152.
40 Gilliland, D.G. The roles of FLT3 in hematopoiesis and leukemia / D.G. Gilliland, J.D. Griffin // Blood. - 2002. - V.100. - I.5. - P.1532-1542.
41 Hannum, C. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs / C. Hannum, J. Culpepper, D.Campbell, [et al] // Nature. - 1994. - V.368. - I.6472. - P.643.
42 Janke, H. Activating FLT3 Mutants Show Distinct Gain-of-Function Phenotypes In Vitro and a Characteristic Signaling Pathway Profile Associated with Prognosis in Acute Myeloid Leukemia / H. Janke, F. Pastore, D. Schumacher, [et al] // PLOS ONE. - 2014. - V.9. - I.3. - P.e89560.
43 Schnittger S. Diversity of the juxtamembrane and TKD1 mutations (Exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data / S. Schnittger, U. Bacher, C. Haferlach, [et al] // Genes Chromos Cancer. - 2012. - V.51. - 1.10. - P.910-24.
44 Kayser S. Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome /
S. Kayser, R.F. Schlenk, M.C. Londono, [et al] // Blood. - 2009. - V.114. - I.12. - P.2386-2392.
45 Matsumura I. Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies / I. Matsumura, M. Mizuki, Y. Kanakura // Cancer Sci. - 2008. - V.99. - P.479-85.
46 Griffith J. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain / J. Griffith, J. Black, C. Faerman, [et al] // Mol Cell - 2004. -V.13. - P.169-78.
47 Gu T. Survey of Activated FLT3 Signaling in Leukemia / T. Gu, J. Nardone, Y. Wang, [et al]. // PLoS ONE. - 2011. - V.6. - I.4. - e19169.
48 Chan P.M. Differential signaling of FLT3 activating mutations in acute myeloid leukemia: a working model. / P.M. Chan // Protein Cell. - 2011. - V.2. -I.2.
- P.108-115
49 Kottaridis P. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials / P. Kottaridis, R. Gale, M. Frew, [et al] // Blood. - 2001. - V.98. -I.6. - P.1752-9.
50 Liu S.B. Impact of FLT3-ITD length on prognosis of acute myeloid leukemia. / S.B. Liu, H.J. Dong, X.B. Bao, [et al] // Haematologica. - 2019. - V.104.
- I.1. - P.9-12
51 Зайкова Е.К. Молекулярная диагностика мутаций гена FLT3 у пациентов с острыми миелоидными лейкозами / Е.К. Зайкова, Е.В. Белоцерковская, Д.В. Зайцев, [и др] // Клиническая онкогематология. - 2020. -
T. 13. - №2. - С. 150-60.
52 Bagrintseva K. FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl- x(L) / K. Bagrintseva, S. Geisenhof, R. Kern, [et al]. // Blood. - 2005. - V.105. - I.9.
- P.3679-85.
53 Wang W. Prevalence and prognostic significance of FLT3 gene mutations in patients with acute leukaemia: analysis of patients from the Shanghai Leukaemia Co-operative Group. / W. Wang, X.Q. Wang, X.P. Xu, G.W. Lin // J Int Med Res. - 2010. - V.38. - I.2. - P.432-442
54 Гук Л.В. Анализ частоты и прогностического значения мутаций генов FLT3, c-KIT и NPM1 у детей с острым миелобластным лейкозом / Л.В. Гук, Т.В. Савицкая, Д.А. Домнинский //Онкогематология. - 2009. - № 4. - С.27-32
55 Thiede C. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identifi cation of subgroups with poor prognosis / C. Thiede, C. Steudel, B. Mohr, [et al]. // Blood - 2002. - V.99. - I.12. - P.4326-35.
56 Lin P. Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia. / P. Lin,
D. Jones, L.J. Medeiros, [et al] // Am J Clin Pathol. - 2006. - V.126 -I.4 - P.530-533
57 Deeb K.K. Deletion and deletion/ insertion mutations in the juxtamembrane domain of the FLT-3 gene in adult acute myeloid leukemia / K.K. Deeb, M.T. Smonskey, H.C. Defedericis, [et al]. // Leuk Res Rep. - 2014. -V.3. - I.2. - P.86-9.
58 Falini B. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features / B. Falini, I. Nicoletti, M. F. Martelli, [et al] // Blood. - 2007. - V.109. - I.3. - P.874-885.
59 Yu Y. Nucleophosmin is essential for ribosomal protein L5 nuclear export / Y. Yu, L.B. Maggi Jr, S.N. Brady, [et al] // Mol Cell Biol. - 2006. - V.26. - P.3798-3809.
60 Fukuda M. CRM1 is responsible for intracellular transport mediated by the nuclear export signal / M. Fukuda, S. Asano, T. Nakamura, [et al]. // Nature. - 1997.
- V.390. - P.308-311.
61 Falini B. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML / B. Falini, N. Bolli, J. Shan, [et al]. // Blood. - 2006. - V.107. - P.4514-4523.
62 Falini B. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype / B. Falini, C. Mecucci, E. Tiacci,[et al].// N Engl J Med. - 2005.
- V.352. - P.254-266.
63 Lin L. A novel fluorescence-based multiplex PCR assay for rapid simultaneous detection of CEBPA mutations and NPM mutations in patients with acute myeloid leukemias / L. Lin, T. Lin, W. Chou, [et al] // Leukemia - 2006. - V.20. - P.1899-1903
64 Wertheim G. Nucleophosmin(NPM1) mutations in acute myeloid leukemia: An ongoing (cytoplasmic) tale of dueling mutations and duality of molecular genetic testing methodologies. / G. Wertheim, A. Bagg // J Mol Diagnost. - 2008. - V.10. - I.3. - P.198-202.
65 Meshinchi S. Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. / S. Meshinchi, R.Arceci // Oncologist. - 2007. - V.12. - P.341¬55.
66 Силин А. Е. Мутационный анализ генов FLT3 и NPM1 в группе взрослых пациентов с миелодиспластическим синдромом и острым нелимфобластным лейкозом / А. Е. Силин, Ж. М. Козич, В. К. Шпудейко // Проблемы здоровья и экологии. - 2011. - С. 85-90.
67 Kumar D. NPM1 Mutation Analysis in Acute Myeloid Leukemia: Comparison of Three Techniques - Sanger Sequencing, Pyrosequencing, and Real-Time Polymerase Chain Reaction. / D. Kumar, A. Mehta, M.K. Panigrahi, [et al] // Turk J Haematol. - 2018. - V.35. -I.1. - P.49-53.
68 Huet S. New Quantitative Method to Identify NPM1 Mutations in Acute Myeloid Leukaemia / S. Huet , L. Jallades, C. Charlot // Leukemia Research and Treatment. -2013. - ID 756703.
69 O’Donnell M.R. Acute myeloid leukemia, version 3.2017, NCCN Clinical Practice Guidelines in Oncology. / M.R. O’Donnell, M.S. Tallman, C.N. Abboud, [et al]. // J Natl Compr Canc Netw. - 2017. - V.15. - I.7. - P.926-57.
70 Kim Y. Quantitative fragment analysis of FLT3-ITD efficiently identifying poor prognostic group with high mutant allele burden or long ITD length / Y. Kim, G.D. Lee, J. Park, [et al]. // Blood Cancer J. - 2015. - V.5. - I.8. - e336.
71 Thiede C. FLT3 mutation Assay Laboratory Cross Validation: Results from the CALGB 10603/Ratify Trial in Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML). / C. Thiede, T. Prior, S. Lavorgna, [et al]. // Blood. - 2018. - V.132. - Suppl_1:2800.
72 Daver N. Targeting FLT3 mutations in AML: review of current knowledge and evidence / N. Daver, R.F. Schlenk, N.H. Russell, [et al]. // Leukemia. - 2019. - V.33. - I.2. - P.299-312.
73 LeukoStrat® CDx FLT3 Mutation Assay [Электронный ресурс] - Режим
доступа: http://invivoshop.wpengine.com/product/leukostrat-cdx-flt3-mutation-
assay/
74 Levis M. FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? / M. Levis // Hematology Am Soc Hematol Educ Program. -
2013. - V.2013. - P.220-6.
75 Tan, A.Y. Detection of NPM1 exon 12 mutations and FLT3 - internal tandem duplications by high resolution melting analysis in normal karyotype acute myeloid leukemia / A.Y. Tan, D.A. Westerman, D.A. Carney, [et al] // J Hematol Oncol. - 2008. - V.1. - I.10.
76 Chang, T.L. Simplified capillary electrophoresis detection of the Flt-3 internal tandem duplications and D835 point mutations in acute myeloid leukemia / T.L. Chang, M. Salto-Tellez, Y.K. Kueh, [et al] // Haematologica. - 2003. - V.88. - I.2. - ELT04.
77 Yamamoto, Y. Nakano, Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies / Y. Yamamoto, H. Kiyoi, Y. Nakano // Blood. - 2001. - V.97. - I.8. - P.2434-2439.
78 DNA Fragment Analysis by Capillary Electrophoresis User Guide,
[Электронный ресурс] - Режим доступа:
https://www.thermofisher.com/ru/ru/home/global/forms/fragment-analysis-guide-registration-form.html
79 Zorn J.A. Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220) / J.A. Zorn, Q. Wang, E. Fujimura, [et al] // PLoS One. - 2015. - V.10. - I.4. - e0121177.
80 Jones A.V. Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms. / A.V. Jones, D. Ward, M. Lyon, [et al.] // LeukRes. - 2015. - V.39. - I.1. - P. 82-87.
81 Shuji O. Sensitive Sequencing Method for KRAS Mutation Detection by Pyrosequencing. / O. Shuji, K. Takako, B. Mohan, [et al]. // The Journal of Molecular Diagnostics. - 2005. - V.7. - I.3. - P.413-21
82 Тест-системы «Онкоскрин-Q» [Электронный ресурс] - Режим доступа: http: //genetechnology. ru/node/100
83 Субботина, Т.Н. Использование гетеродуплексного анализа и пиросеквенирования в алгоритме диагностики истинной полицитемии, ассоциированной с соматическими мутациями в 12 экзоне гена JAK2 / Т.Н. Субботина и др. // Лабораторная служба. - 2017. - Т. 6. - №. 1. - С. 29-33.
84 Farrar, J.S. High-resolution melting curve analysis for molecular diagnostics / J.S. Farrar, C.T. Wittwer // Molecular Diagnostics. - 2017. - V.47. - P. 79-102.

Купить